DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 8, 2006; DOI: 10.1124/dmd.106.009670


0090-9556/06/3409-1556-1562$20.00
DMD 34:1556-1562, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.009670v1
34/9/1556    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donato, M. T.
Right arrow Articles by Gómez-Lechón, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donato, M. T.
Right arrow Articles by Gómez-Lechón, M. J.

Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts

M. Teresa Donato, Agustín Lahoz, Nuria Jiménez, Gabriela Pérez, Alfonso Serralta, José Mir, José V. Castell, and M. José Gómez-Lechón

Unidad de Hepatología Experimental, Centro de Investigación, Hospital La Fe, Valencia, Spain (M.T.D., N.J., G.P., J.V.C., M.J.G.-L.); Departamento de Bioquímica y Biología Molecular, Universidad de Valencia, Valencia, Spain (M.T.D., J.V.C.); Advancell, in Vitro Cell Technologies Valencia, Spain (A.L.); and Unidad de Cirugía y Transplante Hepático, Hospital Universitario La Fe, Valencia, Spain (A.S., J.M.)

Liver grafts discarded for transplantation because of macrosteatosis can constitute a valuable source of human hepatocytes for in vitro metabolic and pharmacotoxicological studies or for therapeutic applications. A condition for using hepatocyte suspensions for these purposes is the preservation of their metabolic competence and, particularly, drug-metabolizing enzymes. A reduction in microsomal cytochrome P450 (P450) activities was observed in fatty livers (>40% steatosis) with respect to normal tissue. Similarly, decreased levels of 7-ethoxycoumarin O-deethylation and testosterone metabolism were observed in human hepatocyte cultures prepared from steatotic liver tissue. To clarify the potential impact of lipid accumulation on human hepatic P450 enzymes, we have used an in vitro model of "cellular steatosis" by incubation of cultured hepatocytes with increasing concentrations (0.25–3 mM) of long-chain free fatty acids (FFA). A dose-dependent accumulation of lipids in the cytosol is induced by FFA mixture. Hepatocytes exposed to 1 mM FFA for 14 h showed lower activity values of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 enzymes than nontreated hepatocytes (about 45–65% reduction). This treatment also produced significant decreases in CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 mRNA to about 55 to 75% of mRNA levels in control cells. Our results suggest that although human hepatocytes isolated from steatotic liver show reduced P450 activities, they are metabolically competent and can be used for drug metabolism studies.


Address correspondence to: M. Teresa Donato, Unidad de Hepatología Experimental, Hospital Universitario La Fe, Avenida Campanar 21, 46009, Valencia, Spain. E-mail: donato_mte{at}gva.es




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
W. V. Zhang, I. Ramzan, and M. Murray
Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic Steatosis
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 770 - 777.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.